Clinical trial
Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer
NCT00116610 · Poniard Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00116610 |
|---|---|
| Title | Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer |
| Official title | A Phase II Study of Picoplatin as Second-Line Therapy for Subjects With Resistant or Refractory Small Cell Lung Cancer |
| Lead sponsor | Poniard Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | picoplatin |
| Enrollment | 75 |
| Start date | Jun 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2008 |
| First posted | Jun 30, 2005 |
| Last update posted | Jan 21, 2009 |
| Countries | Canada, Russia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: